TY - JOUR
T1 - Protein kinase C θ (PKC θ) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)
AU - Duensing, Anette
AU - Joseph, Nora E.
AU - Medeiros, Fabiola
AU - Smith, Felicity
AU - Hornick, Jason L.
AU - Heinrich, Michael C.
AU - Corless, Christopher L.
AU - Demetri, George D.
AU - Fletcher, Christopher D.M.
AU - Fletcher, Jonathan A.
N1 - Funding Information:
This review was supported by the National Natural Science Foundation of China NSFC (No. 81274148) and Beijing Municipal Health System Special Funds of High-Level Medical Personnel Construction (No. 2014-3-063).
PY - 2004/8/1
Y1 - 2004/8/1
N2 - KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.
AB - KIT expression is a key diagnostic feature of gastrointestinal stromal tumors (GISTs), and virtually all of the GISTs express oncogenic forms of the KIT or PDGFRA receptor tyrosine kinase proteins, which serve as therapeutic targets of imatinin mesylate (Gleevec; Novartis, Basel, Switzerland). However, KIT expression can be low in PDGFRA-mutant GISTs, increasing the likelihood of misdiagnosis as other types of sarcoma. We report that the signaling intermediate protein kinase C θ (PKCθ) is a diagnostic marker in GISTs, including those that lack KIT expression and/or contain PDGFRA mutations. PKCθ is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target.
UR - http://www.scopus.com/inward/record.url?scp=3442881363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3442881363&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-04-0559
DO - 10.1158/0008-5472.CAN-04-0559
M3 - Article
C2 - 15289315
AN - SCOPUS:3442881363
SN - 0008-5472
VL - 64
SP - 5127
EP - 5131
JO - Cancer Research
JF - Cancer Research
IS - 15
ER -